

MEDESIS PHARMA PRESENTS A SCIENTIFIC POSTER AT THE CLINICAL TRIALS ON ALZHEIMER'S DISEASE CONFERENCE IN SAN FRANCISCO

Montpellier, November 28, 2022 - 6:00pm – MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates with Aonys[®], its proprietary buccal nanodroplet active ingredient administration technology, will be taking part in the 15th annual Clinical Trials on Alzheimer's Disease (CTAD) conference in San Francisco, from November 29 to December 2, 2022, presenting a poster on its Phase II clinical trial drug candidate, NanoLithium[®] AD.



The Clinical Trials on Alzheimer's Disease (CTAD) international conference is focused exclusively on clinical trials targeting this disease. The main leaders for research into Alzheimer's disease, from the industry and academic sectors, meet up and form partnerships with a view to accelerating the development of effective treatments to fight this disease.

Professor Eugenia Maria Soto Martin, a member of Medesis Pharma's Permanent Scientific Advisory Board¹, accompanied by Ms Solène Guilliot, the company's Director of Medical Affairs and Clinical Development, will present a scientific poster setting out the design of the Phase II trial which aims to demonstrate the impact of NanoLithium[®] on behavioral and psychological symptoms in patients with mild to serious forms of Alzheimer's disease.

Medesis Pharma's NanoLithium[®] research program for the treatment of the psychological and behavioral disorders associated with Alzheimer's disease is currently being developed and has been prepared with Professor Jacques Touchon (former Dean of Montpellier's School of Medicine and Chairman of the last global Alzheimer's conferences in 2019, 2020 and 2021), who is also a member of the CTAD 2022 Scientific Committee and Medesis Pharma's Permanent Scientific Advisory Board.

Since summer 2022, seven teaching hospital centers (Toulouse, Montpellier, Paris, Lille, Lyon, Marseille and Limoges) have been opened. 10 patients have been included to date and three more are currently being integrated out of the 68 to be recruited. The integrations are scheduled to be completed in spring 2023. The first results on the efficacy of NanoLithium[®] for the treatment of the psychological and behavioral disorders associated with this disease could be known by summer 2023 (after three months of treatment), followed by results concerning the development of the disease (biomarkers and imaging) one year later (after 12 months of treatment).

[For more information:](#)

- [Download the poster presented by Medesis Pharma.](#)
- Visit the site for the 15th annual CTAD conference, which will be held in San Francisco from November 29 to December 2, 2022: www.ctad-alzheimer.com

About Medesis Pharma

To advance the treatment of serious diseases without effective treatments, Medesis Pharma creates drug candidates based on its proprietary Aonys[®] technology for the oral administration of active ingredients in nanodroplet form, enabling active ingredients to be effectively delivered to all cells, with passage through the blood-brain barrier (BBB).

This innovative approach is being applied to future drugs to treat major diseases that do not have effective treatments: Alzheimer's disease, Huntington's disease, and certain resistant cancers.

Medesis Pharma is also developing treatments dedicated to populations contaminated or irradiated after a civil or military nuclear accident.

French biopharmaceutical company based near Montpellier, Medesis Pharma is the author of 15 scientific publications, holds 11 patent families and 71 patents, the result of 17 years of research.

Medesis Pharma's shares are listed on Euronext Growth Paris: FR001844464 - ALMDP

For more information:

www.medesispharma.com

MEDESIS PHARMA

Tessa Olivato
Tel: +33 4 67 03 03 96
contact@medesispharma.com

CALYPTUS

Marie Calleux
Tel : +33 1 53 65 68 66
medesispharma@calyptus.net

¹ See the press release from November 21, 2022: https://www.medesispharma.com/wp-content/uploads/2022/11/CP_ScientificAdvisoryBoard_EN.pdf